Biomaterial-guided immobilization and osteoactivity of bone morphogenetic protein-2
Biomaterial-guided immobilization and osteoactivity of bone morphogenetic protein-2
复制标题
生物材料引导下骨形态发生蛋白-2的固定化和成骨活性
DOI：
10.1016/j.apmt.2020.100599
复制
发表时间：
2020-06-01
影响因子：
8.3
通讯作者：
Liu, Changsheng
中科院分区：
文献类型：
--
作者：
Huang, Baolin;Yuan, Yuan;Liu, Changsheng
Growth factors play a key role in directing cell behaviors via providing biochemical cues for cellular adhesion, migration, proliferation, and differentiation. Currently, recombinant human bone morphogenetic protein-2 (rhBMP-2) is the only US Food and Drug Administration-approved osteoinductive growth factor and its clinical application is solely combined with absorbable collagen sponge. Strikingly, the major limitation of rhBMP-2-based therapy is the dosage-related adverse effects. In order to achieve controlledand localized-delivery and thus to relief the side effects of over-physiological usage of rhBMP-2 cytokines, numerous biomaterials with one or more kinds of suitable properties for rhBMP-2 delivery have been developed in the past years. Here, this review reports the history, molecular structures, cellular signaling, delivery vehicles, and clinical applications of rhBMP-2, and highlights the biomaterial-induced positive regulation effects on the structure and bioactivity of rhBMP-2. The mechanisms of biomaterial-modulated osteoactivity are classified in four major categories: (i) localization of rhBMP-2, (ii) upregulation of BMPRs binding affinity, (iii) enhancement of BMPRs expression, and (iv) inhibition of BMP antagonists. In addition, from molecular dynamics viewpoints, the correlation of molecule structures and bioactivity of rhBMP-2 upon biomaterials are discussed. This overview can provide guidelines for the future design of BMP-2-based bone regeneration scaffolds/implants and may open new sparks for growth factor-based regenerative therapies. (C) 2020 Elsevier Ltd. All rights reserved.
